| <P>Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain. </P> <P>This collaboration combines Lupin's global respiratory expertise and proven pMDI manufacturing excellence and ERN's robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.</P> |